{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460123491
| IUPAC_name = (''RS'')-1-(''tert''-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
| image = Bupranolol.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|bupranolol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = Oral, topical (eye drops)

<!--Pharmacokinetic data-->
| bioavailability = < 10%
| protein_bound = 76%
| metabolism = First pass elimination > 90%
| elimination_half-life = 2-4 hours (plasma)
| excretion = > 88% renal (as carboxybupranolol)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 23284-25-5
| CAS_supplemental =  
| ATC_prefix = C07
| ATC_suffix = AA19
| ATC_supplemental =  
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 305380
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HQIRNZOQPUAHHV-UHFFFAOYSA-N
| PubChem = 2475
| IUPHAR_ligand = 550
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08808
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2381
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 858YGI5PIT
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D07590

<!--Chemical data-->
| chemical_formula =  
| C=14 | H=22 | Cl=1 | N=1 | O=2 
| molecular_weight = 271.78298 g/mol
| smiles = CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
}}

'''Bupranolol''' is a non-selective [[beta blocker]] without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to [[propranolol]].

==Uses and dosage==
Like other beta blockers, oral bupranolol can be used to treat [[hypertension]] and [[tachycardia]]. The initial dose is 50&nbsp;mg two times a day. It can be increased to 100&nbsp;mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against [[glaucoma]].

== Pharmacology ==
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo [[first-pass metabolism]]. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1&nbsp;Âµg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid &ndash; that is, the methyl group at the benzene ring is oxidized to a [[carboxyl]] group &ndash;, of which 88% are eliminated renally within 24 hours.

== Adverse effects, contraindications, interactions ==
Adverse effects, contraindications and interactions are similar to other beta blockers.

== References ==
* {{cite book|title=Arzneistoff-Profile|editor1=Dinnendahl, V |editor2=Fricke, U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2007|edition=21|volume=2|isbn=978-3-7741-9846-3|language=German}}

{{beta blockers}}

[[Category:Antiarrhythmic agents]]
[[Category:Beta blockers]]
[[Category:Chloroarenes]]
[[Category:Phenol ethers]]
[[Category:Alcohols]]